Cargando…

Phase I EnACT Trial of the Safety and Tolerability of a Novel Oral Formulation of Amphotericin B

Amphotericin B deoxycholate (AMB) has substantial toxicities. A novel encochleated amphotericin B deoxycholate (cAMB) formulation has oral bioavailability, efficacy in an animal model, and minimal toxicity due to targeted drug delivery into macrophages, where intracellular fungi reside. We conducted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Skipper, Caleb P., Atukunda, Mucunguzi, Stadelman, Anna, Engen, Nicole W., Bangdiwala, Ananta S., Hullsiek, Katherine H., Abassi, Mahsa, Rhein, Joshua, Nicol, Melanie R., Laker, Eva, Williams, Darlisha A., Mannino, Raphael, Matkovits, Theresa, Meya, David B., Boulware, David R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2020
Materias:	Clinical Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508607/ https://www.ncbi.nlm.nih.gov/pubmed/32747357 http://dx.doi.org/10.1128/AAC.00838-20

Ejemplares similares

829. 5-Flucytosine Longitudinal Antifungal Susceptibility Testing of Cryptococcus neoformans: A Sub-study of the EnACT Trial Testing Oral Amphotericin
por: McHale, Thomas, et al.
Publicado: (2023)

869. Oral Encochleated Amphotericin B for Cryptococcal Meningitis: a Phase II Randomized Trial
por: Atukunda, Mucunguzi, et al.
Publicado: (2022)

1716. Baseline Serum C-Reactive Protein Level Predicts Mortality in Cryptococcal Meningitis
por: Chesdachai, Supavit, et al.
Publicado: (2019)

Sterile Cerebrospinal Fluid Culture at Cryptococcal Meningitis Diagnosis Is Associated with High Mortality
por: Skipper, Caleb P, et al.
Publicado: (2022)

Symptoms of COVID-19 Outpatients in the United States
por: Pullen, Matthew F, et al.
Publicado: (2020)

Baseline Serum C-Reactive Protein Level Predicts Mortality in Cryptococcal Meningitis
por: Chesdachai, Supavit, et al.
Publicado: (2020)

2120. Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model
por: Chesdachai, Supavit, et al.
Publicado: (2019)

Management of amphotericin-induced phlebitis among HIV patients with cryptococcal meningitis in a resource-limited setting: a prospective cohort study
por: Ahimbisibwe, Cynthia, et al.
Publicado: (2019)

Detrimental Outcomes of Unmasking Cryptococcal Meningitis With Recent ART Initiation
por: Rhein, Joshua, et al.
Publicado: (2018)

Lessons Learned From Conducting Internet-Based Randomized Clinical Trials During a Global Pandemic
por: Pullen, Matthew F, et al.
Publicado: (2020)

Minimum Inhibitory Concentration Distribution of Fluconazole Against Cryptococcus Species and the Fluconazole Exposure Prediction Model
por: Chesdachai, Supavit, et al.
Publicado: (2019)

Cryptococcal Disease in the Era of “Test and Treat”: Is There Cause for Concern?
por: Abassi, Mahsa, et al.
Publicado: (2017)

Performance of Lipoarabinomannan Assay using Cerebrospinal fluid for the diagnosis of Tuberculous meningitis among HIV patients
por: Kwizera, Richard, et al.
Publicado: (2019)

Diagnosis and Management of Central Nervous System Cryptococcal Infections in HIV-Infected Adults
por: Skipper, Caleb, et al.
Publicado: (2019)

Therapeutic Lumbar Punctures in Human Immunodeficiency Virus–Associated Cryptococcal Meningitis: Should Opening Pressure Direct Management?
por: Kagimu, Enock, et al.
Publicado: (2022)

Standardized Electrolyte Supplementation and Fluid Management Improves Survival During Amphotericin Therapy for Cryptococcal Meningitis in Resource-Limited Settings
por: Bahr, Nathan C., et al.
Publicado: (2014)

Cerebrospinal Fluid Culture Positivity and Clinical Outcomes After Amphotericin-Based Induction Therapy for Cryptococcal Meningitis
por: Rolfes, Melissa A., et al.
Publicado: (2015)

Cerebral Oximetry for Detecting High-mortality Risk Patients with Cryptococcal Meningitis
por: Diehl, John W, et al.
Publicado: (2018)

Seizures in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis: Predictors and Outcomes
por: Pastick, Katelyn A, et al.
Publicado: (2019)

Feasibility of SARS-CoV-2 Antibody Testing in Remote Outpatient Trials
por: Lofgren, Sarah M, et al.
Publicado: (2021)

Prevalence and nature of potential drug-drug interactions among hospitalized HIV patients presenting with suspected meningitis in Uganda
por: Eneh, Prosperity C., et al.
Publicado: (2020)

Tuberculous meningitis diagnosis and outcomes during the Xpert MTB/Rif era: a 6.5-year cohort study in Uganda
por: Cresswell, Fiona V., et al.
Publicado: (2018)

1791 Evaluating Cryptococcal Antigen Lateral Flow Assay by Fingerstick Whole Blood in HIV-Infected Persons with Meningitis
por: Williams, Darlisha, et al.
Publicado: (2014)

Evaluation of the effectiveness of a South African laboratory cryptococcal antigen screening programme using a retrospective cohort and a cluster-randomised trial design
por: DeSanto, Daniel J, et al.
Publicado: (2022)

Hearing Loss in Cryptococcal Meningitis Survivors
por: Lofgren, Sarah, et al.
Publicado: (2017)

Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19
por: Lofgren, Sarah M, et al.
Publicado: (2020)

Association of Hyponatremia on Mortality in Cryptococcal Meningitis: A Prospective Cohort
por: Tugume, Lillian, et al.
Publicado: (2022)

Technical procedures and REDCap tools for internet-based clinical trials
por: Bangdiwala, Ananta S., et al.
Publicado: (2022)

Efficacy of Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis: an open-label dose-ranging study
por: Rhein, Joshua, et al.
Publicado: (2016)

Early ART After Cryptococcal Meningitis Is Associated With Cerebrospinal Fluid Pleocytosis and Macrophage Activation in a Multisite Randomized Trial
por: Scriven, James E., et al.
Publicado: (2015)

1490. Predictors of Early Mortality in HIV-associated Tuberculous Meningitis
por: Kagimu, Enock, et al.
Publicado: (2023)

Cerebrospinal Fluid and Brain Tissue Penetration of Tenofovir, Lamivudine, and Efavirenz in Postmortem Tissues with Cryptococcal Meningitis
por: Nicol, Melanie R., et al.
Publicado: (2019)

1703 Delta-like 1 ligand (DLL) measurement in cerebrospinal fluid for detection of Mycobacterium tuberculosis meningitis
por: Bahr, Nathan, et al.
Publicado: (2014)

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
por: Boulware, David R., et al.
Publicado: (2020)

Evaluation of Fingerstick Cryptococcal Antigen Lateral Flow Assay in HIV-Infected Persons: A Diagnostic Accuracy Study
por: Williams, Darlisha A., et al.
Publicado: (2015)

Impact of community engagement and social support on the outcomes of HIV-related meningitis clinical trials in a resource-limited setting
por: Kwizera, Richard, et al.
Publicado: (2020)

Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study
por: Cresswell, Fiona V, et al.
Publicado: (2020)

Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial
por: Lother, Sylvain A., et al.
Publicado: (2020)

Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial
por: Rajasingham, Radha, et al.
Publicado: (2020)

Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial
por: Rajasingham, Radha, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7345e4875cpi56ohrga991sd89